Neoadjuvant nivolumab with or without platinum-doublet chemotherapy based on PD-L1 expression in resectable NSCLC (CTONG1804): a multicenter open-label phase II study
Abstract This prospective multicenter phase II study evaluated the clinical efficacy of neoadjuvant nivolumab-exclusive (N) and nivolumab–chemotherapy (N/C) combinations based on PD-L1 expression. Eligible patients exhibited resectable clinical stage IIA–IIIB (AJCC 8th edition) NSCLC without EGFR/AL...
Na minha lista:
| Principais autores: | , , , , , , , , , , , , , , , , , , , , , |
|---|---|
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
Nature Publishing Group
2023-12-01
|
| coleção: | Signal Transduction and Targeted Therapy |
| Acesso em linha: | https://doi.org/10.1038/s41392-023-01700-4 |
| Tags: |
Sem tags, seja o primeiro a adicionar uma tag!
|
